LAWRENCEVILLE, N.J. — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in...
treatment News
POMEZIA, Italy – The Menarini Group announced today that additional data have been generated on SEL24/MEN1703, a first-in-class, orally available, dual PIM/FLT3 inhibitor, as part of the DIAMOND-01 trial. The results will be presented at both the upcoming American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) Virtual Congresses. DIAMOND-01...
FLORENCE, Italy – The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML). SEL24/MEN1703 is a first-in-class, orally available, dual PIM/FLT3 inhibitor, in-licensed by Menarini from Ryvu Therapeutics, and currently investigated in...
RAHWAY, N.J. — Merck & Co. (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of pivotal Phase 3 trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors. Global Phase 3 studies have been initiated...
RAHWAY, N.J. — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell...
DARMSTADT, Germany – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) who have failed or are intolerant...
KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a New Drug Application (NDA) for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan (pronounced bell-ZOO-ti-fan), a novel investigational...
Rahway, New Jersey – Merck’s blockbuster PD-1 inhibitor Keytruda (pembrolizumab) improved overall survival when used as an adjuvant treatment for renal cell carcinoma patients who are at intermediate-high or high risk of recurrence after nephrectomy, according to results of the Phase III KEYNOTE-564 trial posted Saturday. Compared with placebo, patients...
RAHWAY, N.J. — Merck & Co. (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced resectable...
Melbourne, Australia and New York, USA – Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatorydiseases, today provided a regulatory update on remestemcel-L for steroid-refractory acute graft versus host disease in children following its recent meeting with the FDA’s OTAT. Mesoblast requested the meeting to address the...